ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months

• Taiwan is ELEVAI’s third Asian contract for exosomes distribution after adding the Philippines in August of 2023 and Vietnam in May 2023
• Asia-Pacific represents a combined $13 Billion prestige skincare and luxury haircare market^4,5
• Immediate access to 40 specialty hair treatment clinics and four (4) high-end medical aesthetic clinics
  

NEWPORT BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC. (NASDAQ: ELAB) (“Elevai” or the “Company”), a medical aesthetic company specializing in physician-dispensed skin care, is pleased to announce that it has signed an international distribution agreement with ILIA International Ltd. (“ILIA”) covering the country of Taiwan.

ILIA is a Taiwan-based sales and marketing distributor of luxury skincare brands utilizing novel, cutting-edge technologies. Under the agreement, ILIA will have exclusive rights to distribute ELEVAI’s patented skincare products throughout Taiwan. ILIA’s near-term sales strategy will be to strategically distribute ELEVAI products to their customers in the country.

Chris Kraneiss, Chief Commercial Officer of Elevai Labs, Inc. commented:

“It is with great pleasure that I announce the signing of ILIA International Ltd. as our exclusive distributor in Taiwan. From my past dealings in the region, I know that ILIA is very well respected in the Taiwanese market and is one of the leading aesthetic distributors in that territory. Exosome-based beauty has some of its earliest roots in the Asian region, and it is a testament to our quality, purity, proprietary technology, and advanced formulations that we have had such a rapid uptake on the continent. We believe that with this agreement ELEVAI will become one of the leading exosome providers in Taiwan, and that ILIA’s access to all leading aesthetic practices and clinics will set us on the proper course.”

Cordelia Huang, Managing Director of ILIA International Ltd., Taiwan commented:

“We are proud to be a part of this opportunity to introduce cutting-edge skincare products from ELEVAI Labs to our high-end medical aesthetics clients in Taiwan. We have strong confidence in ELEVAI’s E-series skincare products’ efficacy in enhancing health and beauty and expect the brand to prevail in this region.”

Demand for Prestige in Taiwan:

According to GLG, a financial and global information services company, beauty trends in Taiwan mirror many of the attributes of Japan’s robust market, but with stronger growth. In Taiwan, the prestige side of the industry leads at 60% of the market share, with mass products taking the other 40%,¹ illustrating outsized demand for higher-end products compared to the US market, which is closer to 50/50².